Overview

Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

Status:
Completed

Trial end date:
2018-07-25

Target enrollment:

Participant gender:

Summary

The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who require additional IOP lowering with LUMIGAN® (bimatoprost) 0.01%.

Phase:

Phase 4

Details

Lead Sponsor:

Allergan

Treatments:

Bimatoprost
Brimonidine Tartrate
Brimonidine Tartrate, Timolol Maleate Drug Combination
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol